[HTML][HTML] Efficacy and safety of a novel nasal steroid, S0597, in patients with seasonal allergic rhinitis
P Badorrek, JM Hohlfeld, N Krug, A Joshi… - Annals of Allergy, Asthma …, 2015 - Elsevier
Background Allergic rhinitis (AR) poses a significant global burden with increasing
prevalence. Although intranasal glucocorticosteroids are effective, older agents can have
limiting side effects. S0597, a novel intranasal glucocorticosteroid, has demonstrated good
safety and tolerability during preclinical and phase 1 studies. Objective To assess the
clinical efficacy, safety, and tolerability of different doses of S0597 nasal spray vs placebo in
patients with seasonal AR. Methods This phase 2, randomized, double-blinded, placebo …
prevalence. Although intranasal glucocorticosteroids are effective, older agents can have
limiting side effects. S0597, a novel intranasal glucocorticosteroid, has demonstrated good
safety and tolerability during preclinical and phase 1 studies. Objective To assess the
clinical efficacy, safety, and tolerability of different doses of S0597 nasal spray vs placebo in
patients with seasonal AR. Methods This phase 2, randomized, double-blinded, placebo …